Evidence map›Paper›PMID 40850683›Full record

ArticleJournal of advanced research2026

Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y

Sheng Tian, Kai Wang, Chunxiao Liu, Xinyu Chen, Xiaotian Kong, Zhoudong Zhang, Gui Shao, Shufan Ren, Qinghua Hu, Huanqiu Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sheng TianCollege of Pharmaceutical Sciences, Jiangsu Key Laboratory of Neuropsychiatric Diseases and Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, Soochow University, Suzhou 215123, China. Electronic address: stian@suda.edu.cn.
Kai WangCollege of Pharmaceutical Sciences, Jiangsu Key Laboratory of Neuropsychiatric Diseases and Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, Soochow University, Suzhou 215123, China.
Chunxiao LiuSchool of Pharmacy and School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China.
Xinyu ChenCollege of Pharmaceutical Sciences, Jiangsu Key Laboratory of Neuropsychiatric Diseases and Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, Soochow University, Suzhou 215123, China.
Xiaotian KongCollege of Chemistry and Life Science, Beijing International Science and Technology Cooperation Base for Intelligent Physiological Measurement and Clinical Transformation, Beijing University of Technology, Beijing 100124, China. Electronic address: kongxt123@bjut.edu.cn.
Zhoudong ZhangCollege of Pharmaceutical Sciences, Jiangsu Key Laboratory of Neuropsychiatric Diseases and Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, Soochow University, Suzhou 215123, China.
Gui ShaoCollege of Pharmaceutical Sciences, Jiangsu Key Laboratory of Neuropsychiatric Diseases and Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, Soochow University, Suzhou 215123, China.
Shufan RenCollege of Pharmaceutical Sciences, Jiangsu Key Laboratory of Neuropsychiatric Diseases and Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, Soochow University, Suzhou 215123, China.
Qinghua HuSchool of Pharmacy and School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China. Electronic address: huqh@cpu.edu.cn.
Huanqiu LiCollege of Pharmaceutical Sciences, Jiangsu Key Laboratory of Neuropsychiatric Diseases and Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, Soochow University, Suzhou 215123, China. Electronic address: huanqiuli@suda.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe P2Y

objectivesThis study aimed to computationally identify FDA-approved or experimental drugs as novel P2Y

methodsA multi-step computational pipeline integrated structure-based virtual screening (SBVS) of DrugBank drug compounds, molecular docking (Glide XP/AutoDock Vina), molecular dynamics (MD) simulations, and MM/GBSA binding free energy calculations. Top candidates underwent in vitro P2Y

resultsChloramphenicol succinate (DB07565), an antibiotic, emerged as a potent P2Y

conclusionThis study demonstrates that computational repurposing successfully identifies DB07565 as a high-affinity P2Y

Indexed as

ChloramphenicolDrug RepositioningInflammatory Bowel DiseasesPurinergic P2 Receptor AntagonistsReceptors, Purinergic P2AnimalsColitisDisease Models, AnimalDrug DiscoveryHumansMiceMice, Inbred C57BLMolecular Docking SimulationMolecular Dynamics SimulationChloramphenicolP2Y14 receptor, humanPurinergic P2 Receptor AntagonistsReceptors, Purinergic P2Drug repurposing approacheIBD treatmentMolecular dynamic simulationP2Y14R antagonistsSBVS

Identifiers

PMID40850683
PMCPMC13154657

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.